Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non Operating Income: 2012-2025

Historic Other Non Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $4.8 million.

  • Catalyst Pharmaceuticals' Other Non Operating Income fell 24.27% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year increase of 82.37%. This contributed to the annual value of $21.1 million for FY2024, which is 174.57% up from last year.
  • Catalyst Pharmaceuticals' Other Non Operating Income amounted to $4.8 million in Q3 2025, which was up 59.20% from $3.0 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Other Non Operating Income high stood at $11.3 million for Q4 2024, and its period low was -$833,000 during Q3 2023.
  • Moreover, its 3-year median value for Other Non Operating Income was $3.0 million (2025), whereas its average is $4.0 million.
  • The largest annual percentage gain for Catalyst Pharmaceuticals' Other Non Operating Income in the last 5 years was 3,008.45% (2022), contrasted with its biggest fall of 622.58% (2022).
  • Catalyst Pharmaceuticals' Other Non Operating Income (Quarterly) stood at $71,000 in 2021, then skyrocketed by 3,008.45% to $2.2 million in 2022, then skyrocketed by 127.23% to $5.0 million in 2023, then skyrocketed by 126.08% to $11.3 million in 2024, then fell by 24.27% to $4.8 million in 2025.
  • Its Other Non Operating Income was $4.8 million in Q3 2025, compared to $3.0 million in Q2 2025 and $7.9 million in Q1 2025.